Skip to content

Taysha Gene Therapies

US · TSHA #3015 by market cap Listed 2020
3.72 -0.05 -1.33%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 3.73 -1.06%
After-hours 3.71 -0.27%
Overnight 3.78 +0.27%
6.943.513.722026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on TSHA?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -22.9% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 16.4% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall D+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Operating margin -1,130.6% Better than 3%
Net margin -1,115.3% Better than 2%
Return on equity -68.5% Better than 7%
Return on invested capital -52.3% Better than 6%
Momentum D+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -38.9% Better than 11%
6-month return -32.2% Better than 17%
12-month return (ex latest month) -5.5% Better than 27%
Distance below 52-week high 49.0% Better than 20%
Financial Health B-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 12.2x Better than 95%
Debt to assets 20.4% Better than 55%
Interest coverage -1,729.1x Better than 2%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 285.2% Better than 97%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -9.27%
1M -9.49%
3M -39.12%
6M -32.24%
YTD -32.36%
1Y -6.77%
3Y +106.67%
5Y -72.42%

Key statistics

Price & volume

Prev close
3.77
Open
3.67
Day range
3.60 - 3.80
Avg price
3.72
Volume
3.15M
Turnover
11.72M
Amplitude
5.17%
52-week range
3.46 - 7.30

Valuation

P/E
-10.94
P/E (TTM)
-8.86
P/B
3.40
EPS
-0.34
Net profit
-110.86M
Net assets
357.02M

Share structure

Market cap
1.21B
Float cap
845.64M
Shares out
326.05M
Float shares
227.32M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2020-09-24
52-week range 7% of range
3.46 7.30

49.0% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-23.00M net over the window

Short interest

Shares short
53.48M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Taysha Gene Therapies (TSHA)?

Taysha Gene Therapies last traded at 3.72. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Taysha Gene Therapies's market cap?

About 1.21B.

What is the P/E ratio of Taysha Gene Therapies?

The trailing twelve-month P/E is -8.86. The Valuation tab shows it against the stock's own five-year range.

Does Taysha Gene Therapies pay a dividend?

Taysha Gene Therapies does not currently pay a regular dividend.

Is Taysha Gene Therapies a buy according to analysts?

The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 14.33, which implies 285.2% upside from the current price. This is not investment advice.

What is Taysha Gene Therapies's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Taysha Gene Therapies a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 20:02:39 · For reference only, not investment advice and not tailored to your situation.

Taysha Gene Therapies discussion 0 comments

Add a comment